Monitoring recurrence of urothelial carcinoma using urinary tests

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

This study is testing if urine tests can help track the return of urothelial carcinoma in patients with different types of bladder and kidney cancer.

Quick facts

• Study type: Observational
• Enrollment: 300 (estimated)
• Ages: 18 Months and up
• Sex: All
• Sponsor: Peking University First Hospital (Academic / other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06991868 on ClinicalTrials.gov

What this trial studies

This multicenter, prospective cohort study aims to monitor the recurrence of urothelial carcinoma by detecting microscopic residual disease (MRD) in urine samples. Patients are divided into four cohorts based on their cancer type and treatment status, including high-risk upper tract urothelial carcinoma, non-muscle invasive bladder cancer, muscle-invasive bladder cancer receiving neoadjuvant therapy, and those evaluated for complete response after standard treatment. The study will assess the sensitivity and specificity of MRD scores in detecting tumor recurrence and remnants. It is an observational study, meaning no experimental treatments are administered.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with pathologically confirmed high-risk upper tract urothelial carcinoma or various stages of bladder cancer.

Not a fit: Patients whose cancer pathology does not meet the study criteria or those unable to comply with follow-up evaluations may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved monitoring and early detection of cancer recurrence in patients with urothelial carcinoma.

How similar studies have performed: While this approach is innovative in its focus on urinary MRD detection, similar studies have shown promise in monitoring cancer recurrence using non-invasive methods.

Eligibility criteria

Cohort I:

Inclusion Criteria:

* patients ≥18 years of age with full civil capacity at the time of signing the informed consent form;
* patients who provide a urine sample for MRD testing at the time of undergoing postoperative review;
* Pathologic type: required to be a pathologically confirmed uroepithelial tumor with a predominantly urothelial tumor with a primary site in the upper urinary tract (including the renal pelvis and ureters), and permitted to contain no more than 50% squamous differentiation, adenomatous differentiation, or sarcomatoid differentiation and are pT3/4 or any TpN+.

Exclusion Criteria:

* Pathology after radical surgery that does not meet the criteria for enrollment;
* Predictable inability to meet the criteria for regular review at our center within 1 year postoperatively;
* Disagreement with regular cystoscopy and/or imaging (at least completion of one of CT or MR or PET/CT, with intervals between reviews as well as the specific items to be determined by the clinician);
* Already definite recurrence or metastasis;
* Concomitant combination of other active malignant neoplastic disease or a history of other malignant neoplastic disease within 5 years (excluding basal cell carcinoma and cervical carcinoma in situ after active treatment)

Cohort II:

Inclusion Criteria:

* patients aged ≥18 years at the time of signing the informed consent form with full civil capacity;
* patients who provided a urine sample for central testing when they underwent postoperative review;
* Pathological type: a pathologically confirmed predominantly uroepithelial tumor with a primary site in the bladder is required, and is permitted to contain no more than 50% squamous differentiation, or adenoidal differentiation carcinoma in situ is permitted to be present or only in situ and the pathologic stage may be T1, Ta, or Tis (Cis)

Exclusion Criteria:

* TUR pathology that does not meet the enrollment criteria;
* predictable inability to meet the regular review at our center within 1 year postoperatively;
* disagreement with regular cystoscopy and/or imaging (the content and type of imaging will be determined by the clinician);
* definite recurrence or metastasis already exists;
* concurrent combination of other active malignant neoplastic disease or a 5-year history of other malignant neoplastic disease history (excluding basal cell carcinoma and cervical carcinoma in situ after active treatment)

Cohort III:

Inclusion Criteria:

* patients aged ≥18 years at the time of signing the informed consent form with full civil capacity;
* patients providing urine samples for centralized testing prior to each cycle of treatment during neoadjuvant therapy;
* pathology type: a predominantly uroepithelial tumor with a TUR surgical pathology primary site in the bladder is required, and is permitted to contain no more than 50% squamous, adenomatous, or sarcomatoid differentiation (iii) Patients with pathologic stage T2 or MIBC on comprehensive imaging despite pathologic stage T1;
* Radical cystectomy after neoadjuvant therapy, including bladder, prostate, and seminal vesicles in men and bladder and uterus in women;
* lymph node dissection at least to the extent of the standard dissection for bladder cancer (including the area of the common iliac arteries below the bifurcation of the iliac arteries bilaterally and the area between the ipsoas and genitofemoral nerve to the ureter);
* the presence of evaluable lesions on imaging based on RECIST 1.1 criteria prior to neoadjuvant therapy.

Exclusion Criteria:

* TUR pathology that does not meet enrollment criteria;
* does not undergo radical total cystectomy or standard surgical scope;
* receives less than 2 cycles of neoadjuvant therapy;
* does not undergo regular imaging evaluations during preoperative neoadjuvant therapy;
* has no evaluable lesions prior to neoadjuvant therapy;
* already has definitively present distant metastases;
* concurrently combines other active malignant neoplastic disease or a history of other malignant neoplastic disease within 5 years (excluding basal cell carcinoma and cervical carcinoma in situ after active treatment).

Cohort IV:

Inclusion Criteria:

* patients aged ≥18 years at the time of signing the informed consent form with full civil capacity;
* patients to provide a urine sample for centralized testing at each review visit;
* pathology type: the TUR surgical pathology is required to be a predominantly urothelial tumor with a primary site in the bladder, and is allowed to contain no more than 50% squamous, adenomatous, or sarcomatous differentiation;
* there should be a centralized imaging to assess a clinical assessment of MIBC prior to TMT treatment;
* patients assessed as clinically CR after undergoing TMT who can continue to retain their bladder and do not require salvage cystotomy.

Exclusion Criteria:

* TUR pathology that does not meet the inclusion criteria;
* predictable inability to meet the regular review at our center within 1 year after surgery;
* no pre-treatment imaging at our center;
* disagreement with regularity of receiving imaging (the clinician decides on the content and type of imaging);
* residual lesions or metastases that are already clearly present;
* concurrent combination of other active malignant neoplastic diseases or a history of other malignant neoplastic diseases within 5 year history of other malignant neoplastic disease (excluding basal cell carcinoma and cervical carcinoma in situ after active treatment).

Where this trial is running

Beijing, Beijing Municipality

• Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Cuijian Zhang, MD.

Conditions NMIBC; MIBC; UTUC; high-risk upper tract urothelial carcinoma; non-muscle invasive bladder cancer; muscle-invasive bladder cancer